Tags : Cell Therapy Technology

Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock

Shots: Editas & BlueRock enter in to research collaboration to develop engineered cell therapies/ allogeneic pluripotent stem cell (PSC) lines by the combination of Editas’ CRISPR & BlueRock’s iPSC in oncology & neurology, cardiology and immunology respectively According to cross-licensing agreement, BlueRock to get non-exclusive & IPR rights for Editas Medicine’s CRISPR technology and Editas […]Read More